Skip to Content
Home | news | Press Releases

Press Releases

Carter on FDA expanding access to COVID-19 antiviral medication

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) will now allow authorized, state-licensed pharmacists to prescribe Paxlovid, an oral treatment for COVID-19. 

Rep. Earl L. “Buddy” Carter (R-GA), a pharmacist by trade, sees this Emergency Use Authorization expansion as the necessary link between COVID-19 patients and treatment: 

“Pharmacists are the most accessible health care professionals in America. This move by the FDA will improve Americans' ability to access timely COVID-19 treatments and keep patients out of the hospital,” said Carter. “I look forward to working with the Biden Administration to ensure pharmacies are adequately reimbursed for these services. Affordable, community-based care for all Americans is an indispensable part of our COVID-19 mitigation strategy.”

BACKGROUND: Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death.